| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Amitriptyline | Major depressive disorders and anxiety | Tablets | 10, 25, 50, 75 and 100 mg |
| Amitriptyline | Major depressive disorders and anxiety | XR tablets | 75 mg |
| Baclofen | Spasticity | Injection | 10 mg/5 ml and 10 mg/20 ml |
| Clonazepam | Epilepsy | Tablets | 0.5 mg and 2 mg |
| Duloxetine * | Major depressive disorders, neuropathic pain, anxiety | Gastro resistant hard capsules | 90 and 120 mg |
| Fampridine | Multiple sclerosis | XR tablets | 10 mg |
| Fingolimod | Multiple sclerosis | Capsules | 0.5 mg |
| Lacosamide | Epilepsy | Oral solution | 10 mg/ml |
| Methocarbamol | Muscle spasms, pain | Film-coated tablets | 1.5 mg |
| Quetiapine * | Psychosis, schizophrenia, bipolar disoder | Orodispersable tablets | 25 and 50 mg |
| Rotigotine | Parkinson's | Patches | 1, 2, 3, 4, 6 and 8 mg/24h |
| Sodium Oxybate | Narcolepsy | Oral solution | 500 mg/ml |
| Tranylcypromine | Depression | Film-coated tablets | 10, 20 and 40 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.